Ligand Pharmaceuticals Incorporated
Financials
Valuation Metrics
Ligand Pharmaceuticals Incorporated's Market Cap is $6.15B. At end of 2025 it was $3.73B. Ranked #1172 of 3,116 in US market (top 38%), #386 of 1,472 on NASDAQ (top 26%), #65 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.15B | US#1,172/3,116 Sec#65/265 |
| Revenue | $291M | US#2,440/3,116 Sec#98/265 |
| Net Income | $197M | US#1,287/3,116 Sec#41/265 |
| Total Assets | $2.19B | US#2,017/3,116 Sec#55/265 |
| Net Assets | $968M | US#1,777/3,116 Sec#68/265 |
| Employees | 47 | US#2,705/3,116 Sec#210/265 |
| Value | ||
| P/E | 31.19x | US#1,618/3,116 Sec#44/265 |
| P/B | 6.36x | US#2,390/3,116 Sec#165/265 |
| P/S | 21.17x | US#2,854/3,116 Sec#147/265 |
| EV/EBITDA | 22.93x | US#2,043/3,116 Sec#54/265 |
| FCF Yield | 2.14% | US#2,017/3,116 Sec#67/265 |
| Profitability | ||
| ROE | 20.38% | US#561/3,116 Sec#30/265 |
| ROA | 9.02% | US#547/3,116 Sec#39/265 |
| Op. Margin | 34.74% | US#401/3,116 Sec#22/265 |
| Revenue Growth | 54.89% | US#195/3,116 Sec#46/265 |
| Financial Health | ||
| Debt Ratio | 125.93% | US#1,301/3,116 Sec#173/265 |
| Total Debt | $1.13B | US#1,461/3,116 Sec#43/265 |
| FCF | $131M | US#1,614/3,116 Sec#58/265 |
| Cash | $1.01B | US#683/3,116 Sec#31/265 |
| Current Ratio | 31.18x | US#79/3,116 Sec#11/265 |
| Net Debt/EBITDA | 0.46x | US#762/3,116 Sec#39/265 |
| Performance | ||
| 1Y Return | 60.46% | US#293/3,116 Sec#55/265 |
| 1M Return | 1.33% | US#1,620/3,116 Sec#107/265 |
| From 52W High | -6.02% | US#295/3,116 Sec#25/265 |
| 1Y MDD | -14.70% | US#255/3,116 Sec#7/265 |
| Trading | ||
| Volume | 222,487 shares | US#2,479/3,116 Sec#234/265 |
| Trading Value | $70M | US#949/3,116 Sec#58/265 |
| Per Share | ||
| EPS | $9.84 | US#303/3,116 Sec#9/265 |
| BPS | $48.28 | US#463/3,116 Sec#8/265 |
Company Info
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.